Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone.

Alkharabsheh, Omar; Bellman, Polina; Mahmoudjafari, Zahra; Cui, Wei; Atrash, Shebli; Paul, Barry; Hashmi, Hamza; Shune, Leyla; Ahmed, Nausheen; Abdallah, Al-Ola

Alkharabsheh, Omar; Bellman, Polina; Mahmoudjafari, Zahra; Cui, Wei; Atrash, Shebli; Paul, Barry; Hashmi, Hamza; Shune, Leyla; Ahmed, Nausheen; Abdallah, Al-Ola.

Afiliação

Alkharabsheh O; Division of Medical Oncology, University of South Alabama Mitchell Cancer Institute, Mobile, AL, USA.
Bellman P; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.
Mahmoudjafari Z; University of Kansas Medical Center, Westwood, KS, USA.
Cui W; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.
Atrash S; University of Kansas Medical Center, Westwood, KS, USA.
Paul B; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.
Hashmi H; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Shune L; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.
Ahmed N; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Abdallah AO; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.

J Hematol ; 12(1): 1-6, 2023 Feb.

Article em En | MEDLINE | ID: mdl-36895290

Palavras-chave

Daratumumab; Hematologic toxicity; Pomalidomide; Relapsed multiple myeloma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Hematol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google